Brean Murray Carret & Co. Upgrades Onyx Pharmaceuticals (ONXX) to Buy; Misleading Documents...FDA Approval Is Coming
Tweet Send to a FriendGet Alerts ONXX Hot Sheet
Price: $85.54 -3.67%
Rating Summary:
20 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Rating Summary:
20 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Trade ONXX Now!
Brean Murray Carret & Co. upgraded Onyx Pharmaceuticals (NASDAQ: ONXX) from Hold to Buy with a price target of $60.00.
Analyst, Jonathan Aschoff, said, "Although there was some hesitance of the panel member's decisions, the vote was undeniably positive with 11 yes votes and 1 abstention. More importantly, the FDA clearly supported approval throughout the panel, and the agency has the final say. In our view, there was an unprecedented showing by ODAC head Richard Pazdur, one that was surprising supportive of the drug in question. The portion of Monday's misleading briefing documents that were written by the FDA were utterly useless in guiding our expectation of the panel outcome...With what clearly appears to be a Kyprolis approval on July 27, we upgrade shares."
Ashoff lowers FY12 loss from (3.78) to (3.56) and FY13 from (2.76) to (1.83)
For an analyst ratings summary and ratings history on Onyx Pharmaceuticals click here. For more ratings news on Onyx Pharmaceuticals click here.
Shares of Onyx Pharmaceuticals closed at $44.58 yesterday, with a 52 week range of $27.17-$47.80.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Jonathan Aschoff, said, "Although there was some hesitance of the panel member's decisions, the vote was undeniably positive with 11 yes votes and 1 abstention. More importantly, the FDA clearly supported approval throughout the panel, and the agency has the final say. In our view, there was an unprecedented showing by ODAC head Richard Pazdur, one that was surprising supportive of the drug in question. The portion of Monday's misleading briefing documents that were written by the FDA were utterly useless in guiding our expectation of the panel outcome...With what clearly appears to be a Kyprolis approval on July 27, we upgrade shares."
Ashoff lowers FY12 loss from (3.78) to (3.56) and FY13 from (2.76) to (1.83)
For an analyst ratings summary and ratings history on Onyx Pharmaceuticals click here. For more ratings news on Onyx Pharmaceuticals click here.
Shares of Onyx Pharmaceuticals closed at $44.58 yesterday, with a 52 week range of $27.17-$47.80.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: BofA/Merrill Lynch Upgrades Adobe (ADBE) to Buy
- UPDATE: Bernstein Cuts BlackBerry (BBRY) to Underperform; Notes Weak BB10 Traction
- AcelRx (ACRX) Target Lifted at Jefferies
Create E-mail Alert Related Categories
Analyst EPS Change, FDA, UpgradesRelated Entities
Brean Murray Carret & Co.
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
